Literature DB >> 17909074

Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.

Marco Ruggeri1, Francesco Rodeghiero, Alberto Tosetto, Giancarlo Castaman, Francesca Scognamiglio, Guido Finazzi, Federica Delaini, Caterina Micò, Alessandro M Vannucchi, Elisabetta Antonioli, Valerio De Stefano, Tommaso Za, Luigi Gugliotta, Alessia Tieghi, Maria Gabriella Mazzucconi, Cristina Santoro, Tiziano Barbui.   

Abstract

A multicenter retrospective analysis was performed to estimate the frequency of thrombosis and hemorrhage after surgical procedures in patients with polycythemia vera (PV) and patients with essential thrombocythemia (ET). Data from 105 patients with PV and 150 patients with ET were analyzed, for a total of 311 surgical interventions. An emergency procedure was performed in 25 (8.1%) patients; 194 surgeries were done under general anesthesia, and 21 (23%) of 91 abdominal interventions were done under laparoscopy; 155 (50.1%) were major surgeries. Subcutaneous heparin was administered in 169 (54.3%) of 311 cases and antiplatelet therapy in 48 (15.4%) of 311 case interventions. One hundred eighty-eight (74%) of 255 patients were on cytoreductive therapy before surgery. No events were observed in 259 (83.2%) of 311 procedures during 3 months of follow-up; there were 12 arterial and 12 venous thrombotic events, 23 major and 7 minor hemorrhages, and 5 deaths. Arterial thromboses were more frequent in ET (5.3% vs 1.5%; P=.08), venous events were more frequent in PV (7.7% vs 1.1%; P=.002). There was not a correlation between bleeding episodes and the type of diagnosis, use of antithrombotic prophylaxis, or type of surgery. A high proportion of PV and ET surgeries was complicated by vascular occlusion (7.7%) or by a major hemorrhage (7.3%). Prospective investigations analyzing the optimal prophylaxis in these patients are suggested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909074     DOI: 10.1182/blood-2007-07-102665

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Special issues in myeloproliferative neoplasms.

Authors:  Tiziano Barbui; Guido Finazzi
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

Review 3.  Polycythemia Vera Management and Challenges in the Community Health Setting.

Authors:  Aaron T Gerds; Kim-Hien Dao
Journal:  Oncology       Date:  2017-01-18       Impact factor: 2.935

Review 4.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

5.  Cardiac surgery in a patient with essential thrombocythemia: a case report.

Authors:  B E Schölzel; H Endeman; W Dewilde; A Yilmaz; O de Weerdt; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-08       Impact factor: 2.380

6.  Laparoscopic hepatectomy in a patient with uncontrolled polycythaemia vera.

Authors:  T R Riekki; E Ling; D Cordovani
Journal:  Anaesth Rep       Date:  2019-12-04

7.  From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Authors:  Brady L Stein; Karlyn Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

Authors:  Michelle Ann Elliott; Animesh Pardanani; Terra L Lasho; Susan M Schwager; Ayalew Tefferi
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

9.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

Review 10.  Extreme thrombocytosis and cardiovascular surgery: risks and management.

Authors:  Ethan A Natelson
Journal:  Tex Heart Inst J       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.